$VCEL News
Last published 6d ago
- 6d agoVCELVericel Corporation Third Quarter 2026 - VERICEL CORPEarnings Call TranscriptsGood day and welcome to the VeriCell Corporation third quarter 2026 earnings call. Today's conference is being recorded. If you would like to ask a question on today's call, please press star 1 on your telephone keypad.
- 6d agoVCELVericel Corp - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 6d agoVCELVericel Reports Third Quarter 2026 Financial Results and Raises Full-Year Financial GuidanceGlobeNewswireTotal Revenue Growth of 26% to $85.4 MillionNet Income Increased 179% to $14.2 MillionAdjusted EBITDA Margin of 30%Raised Full-Year Revenue Guidance to $344 to $346 Million and Adjusted EBITDA Margin Guidance to
- 2w agoVCELVericel to Report Third Quarter 2026 Financial Results on November 5, 2026GlobeNewswireBURLINGTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report
- 1mo agoCNXUSOLVVCELAXGN+1Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.GlobeNewswireRENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - The global advanced wound care market is valued at $13.37 billion in 2025 and is projected to reach $19.32 billion by 2030, a
- 1mo agoVCELVericel Corporation - 1774022 - VERICEL CORPEarnings Call TranscriptsThank you very much. This is Peter Harrison from Morgan Stanley Investment Banking Group. I'd like to welcome you to the VeriCell chat. Today with us is Nick Colangelo, the CEO, and Joe Mara, the CFO. With that, we'll ge
- 2mo agoVCELVericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026GlobeNewswireBURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will
- 3mo agoCNXUVCELAXGNKRYS+1Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill ItGlobeNewswireRENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy
- 3mo agoVCELVericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase ProgramGlobeNewswireTotal Revenue Increased 22% to $77.5 Million, with MACI Revenue Growth of 23% Net Income of $2.2 Million and Free Cash Flow of $14.3 Million Full-Year 2026 Revenue Guidance Raised to $330 to $340 Million Board of
- 3mo agoVCELVericel to Report Second Quarter 2026 Financial Results on July 30, 2026GlobeNewswireBURLINGTON, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report
- 4mo agoCNXUIARTMDXGORGO+1Regenerative Medicine's Next Chapter: Inside the Race to Make the Body Rebuild ItselfGlobeNewswireIssued on behalf of Conexeu Sciences Inc. A sector analysis of regenerative medicine — the science of restoring tissue rather than merely replacing it — and where a new generation of platform companies is trying to fit
- 4mo agoCNXUIARTMDXGORGO+1The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding ItGlobeNewswireIssued on behalf of Conexeu Sciences Inc. A new generation of tissue companies is betting that the future of wound care and reconstruction isn't a better patch — it's a material that helps the body regrow
- 5mo agoVCELVericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026GlobeNewswireBURLINGTON, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present
- 5mo agoAXGNCNXUDDDESTA+1The Newest Name on Nasdaq Wants to Help the Body Rebuild ItselfGlobeNewswireIssued on behalf of Conexeu Sciences Inc.A biotech debut out of Reno is betting that the next wave of medicine won't replace tissue — it'll grow it back.NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Energy Metal News News
- 6mo agoVCELVericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial GuidanceGlobeNewswireTotal Revenue Increased 30% to $68.4 Million, with MACI Revenue Growth of 22% and Burn Care Revenue Growth of 91% Gross Margin of 72% and Adjusted EBITDA Growth of 195% Free Cash Flow of $15.1 Million Full-Year 2026
- 6mo agoVCELVericel to Report First-Quarter 2026 Financial Results on May 7, 2026GlobeNewswireCAMBRIDGE, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report
- 7mo agoVCELSANALCTXELDNWhy Smart Money Is Shifting From Clinical Data to Manufacturing LinesPR NewswireThe global cell therapy manufacturing market is on track to nearly double, from $7.17 billion in 2026 to over $14 billion by 2035[1]. The science has ...
- 7mo agoMDWDVCELMediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 MillionGlobeNewswireMediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics
- 7mo agoVCELVericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBridGlobeNewswireCAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, has been awarded a ten-year contract valued
- 8mo agoVCELVericel Announces FDA Approval of New State-of-the-Art Advanced Therapy Manufacturing FacilityGlobeNewswireCompany Achieves Significant Regulatory and Operational Milestone Substantially Increases Manufacturing Capacity to Support Long-Term Growth Enables Potential MACI Commercialization Outside of the U.S. CAMBRIDGE,
- 8mo agoVCELVericel to Present at Multiple Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present
- 8mo agoVCELVericel Reports Fourth Quarter and Full-Year 2025 Financial ResultsGlobeNewswireTotal Revenue of $276.3 Million, with MACI Revenue Growth of 21% to $239.5 Million Net Income Growth of 59% to $16.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% Record Fourth Quarter Gross
- 9mo agoVCELVericel to Report Fourth-Quarter and Full-Year 2025 Financial Results on February 26, 2026GlobeNewswireCAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report
- 10mo agoVCELVericel Announces Preliminary 2025 Financial Results and Business UpdatesGlobeNewswireTotal Revenue Expected to be $276 Million MACI Revenue Expected to be $239.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% CAMBRIDGE, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Vericel
- 10mo agoVCELVericel to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026GlobeNewswireCAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present
- 12mo agoVCELVericel to Present at the Stephens Annual Investment Conference on Thursday, November 20, 2025GlobeNewswireCAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will
- 1y agoVCELVericel Reports Third Quarter 2025 Financial ResultsGlobeNewswireRecord Third Quarter Total Revenue of $67.5 Million MACI Revenue Growth of 25% to $55.7 Million Net Income of $5.1 Million and Adjusted EBITDA Margin of 25% Record Third Quarter Operating Cash Flow of $22.1 Million
- 1y agoVCELVericel to Report Third-Quarter 2025 Financial Results on November 6, 2025GlobeNewswireCAMBRIDGE, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report
- 1y agoVCELVericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025GlobeNewswireCAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will
- 1y agoVCELVericel Corporation (VCEL) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoVCELVericel Reports Second Quarter 2025 Financial ResultsGlobeNewswireTotal Revenue Growth of 20% to $63.2 Million, with MACI Revenue Growth of 21% to $53.5 Million Gross Margin Increased More than 400 Basis Points to 74% Adjusted EBITDA Growth of 112% to $13.4 Million, with Adjusted
- 1y agoVCELVericel to Report Second-Quarter 2025 Financial Results on July 31, 2025GlobeNewswireCAMBRIDGE, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report
- 1y agoVCELVericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025GlobeNewswireCAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company
- 1y agoVCELVericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability GuidanceGlobeNewswireRecord First Quarter MACI Revenue of $46.3 Million and First Quarter Total Revenue of $52.6 Million Approximately 400 MACI Arthro Surgeons Trained to Date, with Year-to-Date Biopsy Growth Over 30% for
- 1y agoVCELVericel to Present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025GlobeNewswireCAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present
- 1y agoVCELVericel to Report First-Quarter 2025 Financial Results on May 8, 2025GlobeNewswireCAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report
- 1y agoVCELVericel to Present at Multiple Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present
- 1y agoVCELVericel Reports Fourth Quarter and Full-Year 2024 Financial ResultsGlobeNewswireFull-Year Total Revenue Growth of 20% to $237.2 Million, with MACI Revenue Growth of 20% and Burn Care Revenue Growth of 22% Full-Year Adjusted EBITDA Growth of 58% to $53.4 Million Record Fourth Quarter Gross Margin
- 1y agoVCELVericel to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 27, 2025GlobeNewswireCAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report
- 1y agoVCELVericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability TargetsGlobeNewswireFull-Year 2024 Total Revenue Growth of 20% and Adjusted EBITDA Growth of Approximately 55% MACI Full-Year 2024 Revenue Growth of 20%, with Fourth Quarter Revenue of $68.2 to $68.7 Million Highest Quarterly MACI
- 1y agoVCELVericel to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025GlobeNewswireCAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present
- 2y agoVCELVericel Corporation (VCEL) Q3 2024 Earnings Conference Call TranscriptEarnings Call Transcripts
- 2y agoVCELVericel Reports Third Quarter 2024 Financial ResultsGlobeNewswireTotal Revenue Growth of 27% to $57.9 Million Gross Margin of 72% and Adjusted EBITDA Growth of 84% Full-Year Profitability Guidance Raised FDA Approval and Commercial Launch of MACI Arthro in Third Quarter Conference
- 2y agoVCELVericel to Report Third-Quarter 2024 Financial Results on November 7, 2024GlobeNewswireCAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its
- 2y agoVCELVericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024GlobeNewswireCAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo,
- 2y agoVCELVericel Announces FDA Approval and Commercial Availability of MACI ArthroGlobeNewswireFirst Restorative Biologic Cartilage Repair Product Approved for Arthroscopic Administration Targets the Largest Segment of MACI's $3 Billion Addressable Market CAMBRIDGE, Mass., Aug. 26, 2024 (GLOBE NEWSWIRE) --
- 2y agoVCELVericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal BurnsGlobeNewswireApproval Expands NexoBrid Target Customer Base to Include Approximately 20 Pediatric Burn Centers CAMBRIDGE, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies
- 2y agoVCELVericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024GlobeNewswireCAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President
- 2y agoVCELVericel Corporation (VCEL) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoVCELVericel Reports Second Quarter 2024 Financial ResultsGlobeNewswireTotal Revenue of $52.7 Million, with MACI Revenue Growth of 21% to $44.1 Million NexoBrid Revenue Growth of 76% Over Prior Quarter Gross Margin of 70% and Adjusted EBITDA Growth of 42% Full-Year